teaser
Takeda Pharmaceuticals has announced that pioglitazone is now licensed for use in combination with insulin in type 2 diabetes mellitus patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance.
Published on 7 February 2007
New combination diabetes treatment
Most read
1
Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
